## ADMA: ADMA Biologics Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.4% below STRENGTH zone (3.0-6.0%); PEG 1.34 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Thrivent Financial for Lutherans Raises Stock Holdings in ADMA Biologics Inc $ADMA**
- Source: MarketBeat | 20251215T121006 | Neutral | Relevance: 100%
- Thrivent Financial for Lutherans significantly increased its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 78.1% in Q2, now holding 3,315,425 shares valued at over $60 million. This move comes as ADMA Biologics reported strong Q2 earnings, meeting analyst expectations with $0.16 EPS and a 12% revenue increase, alongside robust profitability metrics. Despite a recent downgrade to "hold" by Weiss Ratings, the broader analyst consensus remains a "Buy" with a target price of $28.50.

**2. Cim LLC Acquires New Holdings in ADMA Biologics Inc $ADMA**
- Source: MarketBeat | 20251214T100940 | Somewhat-Bullish | Relevance: 100%
- Cim LLC has acquired a new stake of 90,821 shares in ADMA Biologics Inc, valued at approximately $1.65 million, during the second quarter. Several other institutional investors also adjusted their positions in ADMA, with overall institutional ownership now standing at 75.68%. Despite a recent downgrade by Weiss Ratings from "buy" to "hold," the consensus analyst rating for ADMA Biologics remains a "Buy" with a price target of $28.50.

**3. Precision Trading with Adma Biologics Inc (ADMA) Risk Zones**
- Source: Stock Traders Daily | 20251213T165400 | Somewhat-Bearish | Relevance: 100%
- This article provides a precision trading analysis for Adma Biologics Inc (ADMA), highlighting neutral near-term readings and mid-term strong sentiment. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report also notes an exceptional 51.2:1 risk-reward short setup.

**4. ADMA Biologics Inc $ADMA Holdings Decreased by AWM Investment Company Inc.**
- Source: MarketBeat | 20251213T110848 | Neutral | Relevance: 100%
- AWM Investment Company Inc. reduced its stake in ADMA Biologics Inc. by 9.3% during the second quarter, now holding 2.2 million shares valued at $40.06 million, representing 4.5% of its portfolio. Despite this, several other institutional investors increased their positions in ADMA Biologics. The company's stock has a "Buy" consensus rating and an average target price of $28.50, following its recent earnings report that met analyst expectations.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.08M) |
| Sells | 1 ($0.10M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.0% (-2.3%)
- Vanguard Group Inc: 8.8% (-1.8%)
- State Street Corpora: 5.7% (+12.3%)
- Invesco Ltd.: 5.2% (-2.4%)
- Sachem Head Capital : 3.8% (+100.0%)

### Key Risks

1. Elevated short interest (9.6%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.34 suggests fair value with growth premium. Forward P/E 21.0x attractive for 57% earnings growth. Quality metrics strong (ROE 63%, ROA 22%, margin 43%). Balance sheet: strong liquidity (7.1x), low leverage (D/E 0.32). Revenue growth strong at 24% YoY. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.7B |
| Beta | 0.43 |
| 52W Range | $13.50 - $25.67 |
| Short Interest | 9.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.34 |
| Forward P/E | 21.0 |
| Current P/E | 32.9 |
| YoY Growth | 56.7% |
| EPS Direction | RISING |

### Technicals

MRS_10 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 1.6pp (needs >3.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.38% (CS: 39) | Neutral |
| RSI_14 | 64.4 | Neutral |
| MACD Histogram | -0.01 | Bearish |
| vs SMA20 | 1.056x | Above |
| vs SMA50 | 1.197x | Above |
| vs SMA200 | 1.090x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $19.73
- **Stop Loss:** $18.31 (7.2% risk)
- **Target:** $21.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 845
- **Position Value:** $16,671.85
- **Portfolio %:** 16.67%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-03-02 (Est: $0.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.16 | +2.6% |
| 2025Q2 | $0.14 | $0.14 | +7.4% |
| 2025Q1 | $0.17 | $0.11 | -33.3% |
| 2024Q4 | $0.15 | $0.14 | -9.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*